Anti-CD20 monoclonal antibodies (mAbs) labeled with 111In (111In-ibritumomab) for imaging, 90Y (90Y-ibritumomab, Zevalin) for therapy and 131I (131I-tositumomab, Bexxar) for imaging and therapy have been approved for use in patients with NHL (5-8). The gene discussed is MS4A1; the disease is non-Hodgkin lymphoma.